UC Irvine UC Irvine Previously Published Works

Title

SARS-Cov-2 Infection and Seroconversion Rates in Healthcare Providers Prior to COVID-19 Vaccine Rollout

Permalink

https://escholarship.org/uc/item/4rm1f8tc

Authors

Shin, Sanghyuk S Bender, Miriam Malherbe, Delphine C <u>et al.</u>

Publication Date

2023-03-04

DOI

10.1177/10998004231161632

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial License, available at <u>https://creativecommons.org/licenses/by-nc/4.0/</u>

Peer reviewed

SARS-Cov-2 Infection and Seroconversion Rates in Healthcare Providers Prior to COVID-19 Vaccine Rollout

Biological Research For Nursing 2023, Vol. 0(0) I–II © The Author(s) 2023

Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/10998004231161632 journals.sagepub.com/home/brn

Sanghyuk S. Shin, PhD¹, Miriam Bender, PhD RN¹, Delphine C. Malherbe, PhD², Hannah Vasquez, BS¹, Brianna M. Doratt, Msc², and Ilhem Messaoudi, PhD²

Abstract

Objective: A 6-month longitudinal surveillance study of asymptomatic healthcare providers (HCP) was carried out at a large urban academic medical center in the United States to assess whether their job occupation with higher exposure risks to SARS-CoV-2 would equate with higher risk of contracting COVID-19 at the beginning of the pandemic before COVID-19 vaccines were available. **Methods:** A longitudinal cohort study design was used to collect and analyze immunological and virological monitoring data and self-report survey assessments of personal protective equipment (PPE) availability, adherence to infection control guidelines, and time spent on COVID-19 wards. **Results:** Among 289 eligible participants, SARS-CoV-2 exposure risk was high with 48–69% participants working in COVID-19 units and more than 30% of them caring for COVID-19 patients. However, the seroconversion rate was low with only 2.1% of participants developing humoral or cellular immunity against SARS-CoV-2. **Conclusion:** Our study findings suggest that, for this HCP cohort working at a large urban academic medical center, a low incidence of SARS-CoV-2 infection could be maintained under conditions of strict infection prevention protocols and reliable PPE availability.

Keywords

healthcare worker, exposure risk, SARS-CoV-2, infection rate, seroconversion rate

Introduction

Healthcare providers (HCP) are at higher risk of exposure to SARS-CoV-2 than the general population (Houlihan et al., 2020; McCauley & Hayes, 2020; Nguyen et al., 2020). Moreover, because SARS-CoV-2 is a respiratory virus, aerosol-generating procedures increase the risk of transmission of SARS-CoV-2 to HCPs (Tran et al., 2012). Thus, HCPs working in COVID-19 units may be at greater risk of contracting SARS-CoV-2 compared to those who are not working in COVID-19 facing areas (Eyre et al., 2020; Houlihan et al., 2020; Ip et al., 2004; Kucharski & Nilles, 2020). As of July 20, 2022, almost 940,000 COVID-19 cases have been reported in healthcare personnel with close to 2300 deaths out of 527,243 cases for which death status is available (https://covid.cdc. gov/covid-data-tracker/#health-care-personnel). During the early stage of the pandemic (prior to July 2020), nurses constituted 30% of reported HCPs with COVID-19, making them the largest reported occupation with SARS-CoV-2 infection (Hughes et al., 2020). However, the relative risk of acquiring COVID-19 in a hospital setting versus community during the early phase of the pandemic remains poorly

understood. This is further complicated by the fact that $\sim 70\%$ of the infections are asymptomatic (Daria & Islam, 2022) and testing of asymptomatic workers was a workplace-dependent decision that did not get implemented until later in the pandemic.

The risk of SARS-CoV-2 infection among HCPs may be substantially reduced by infection control practices and policies in health care facilities. Early in the pandemic, guidelines were put in place to protect HCPs including diligent cleaning and disinfection, use of personal protective equipment (PPE), isolation, cohorting, and universal masking policy (Bielicki et al., 2020; Richterman et al., 2020). However, access to PPE

Corresponding Author:

¹Sue & Bill Gross School of Nursing, University of California, Irvine, CA, USA ²Department of Microbiology, Immunology and Molecular Genetics, College of Medicine, University of Kentucky, Lexington, KY, USA

Ilhem Messaoudi, PhD, Department of Microbiology, Immunology and Molecular Genetics, 760 Press Ave, Room 552, University of Kentucky Lexington, KY 40536, USA. Email: ilhem.messaoudi@uky.edu

in 2020 was challenging due to global supply shortages and increased demand, particularly during the early stages of the pandemic. PPE shortages were reflected in a nationwide May 2020 survey reporting 87% of nurses had to reuse a single-use disposable mask or N95 respirator and 27% were exposed to confirmed COVID-19 patients without wearing appropriate PPE (National Nurses United, 2020).

Objective

In this study to assess whether job occupation with higher exposure risks to SARS-CoV-2 would equate with higher risk of contracting COVID-19 at the beginning of the pandemic before COVID-19 vaccines were available, we carried out a 6month longitudinal surveillance study in 2020 at the University of California Irvine Medical Center (UCIMC) in Orange County, CA, the sixth most populous county in the USA. The county experienced surges in COVID-19 hospitalizations during summer and fall 2020. For this study, asymptomatic HCPs were enrolled in late April 2020 and followed up until early November 2020, thus covering the summer surge. This study was initiated prior to the adoption of weekly asymptomatic screening at UCIMC. Nasopharyngeal swabs and blood collections were scheduled at four timepoints during this period for virological and serological monitoring. Blood samples were assessed for presence of SARS-CoV-2 specific binding and neutralizing antibody responses as well as SARS-CoV-2 specific T cell responses, while nasopharyngeal swabs were used to test for the presence of viral RNA. Immunological and virological data were then integrated with self-report survey assessments of PPE availability, adherence to infection control guidelines, and time spent on COVID-19 wards.

Materials and Methods

Study Setting and Population

This study was approved by the UC Irvine Human Research Protection committee. Data for this prospective observational study were collected between April 2020–October 2020 at UC Irvine Health's Douglas Hospital, a 417-bed acute care academic medical center in southern California. The sample consisted of multidisciplinary clinicians practicing at the front lines caring for patients, including registered nurses, physicians, physical therapists, and non-licensed care facilitators.

Recruitment was achieved by visits of the designated units during 2 weeks in April 2020. Interested HCPs were emailed recruitment flyers, which included a link to an online REDCap survey. Listed exclusion criteria included: (1) signs and symptoms of COVID-19 (fever and shortness of breath), and (2) prior history of laboratory confirmed COVID-19 infection. Eligible HCPs were provided with informed consent and contact information for study investigators to ask questions. Consenting participants were asked to follow data collection procedures at 1–2-month intervals. Procedures at each time point included: (1) complete a 30-minute online questionnaire; and (2) schedule a visit to the study lab for specimen collection (blood draw and nasopharyngeal swab).

The online questionnaire collected participant demographic information such as job title, job setting, personal characteristics, and recent history of potential interactions related to transmission risk. Survey items included: occupational role, time spent in the unit, exposure to COVID-19 patients, intubation and other procedures performed, use and availability of PPE, and travel history. For occupation, participants were asked "What is your clinical role?" and provided with a dropdown list of occupational roles with an option to specify "Other" and type in their role. For exposure to COVID-19 patients in the hospital, participants were asked the following questions: (1) "Have you actively been assigned to care for patients diagnosed with COVID-19 in the past 30 days?"; (2) "Were there patient(s) diagnosed with COVID-19 in the unit(s) you worked in the past 30 days?"; and (3) "Have you performed or assisted with a medical operation with a high exposure risk to COVID-19 in the past 30 days?" For symptom history, participants were asked, "Have you had any of the following symptoms in the past 30 days?" and were provided with a list of symptoms to select. A question about N95 respirator availability was added after the first round of data collection. Cohort IDs were de-identified and the 10 participants positive for antibody or T cell responses were attributed numbers 1-10 for this publication.

Binding Antibody Titers (ELISA)

Binding antibody titers against Nucleocapsid (NP) and receptor binding domain (RBD) were determined by an in-house enzyme-linked immunosorbent assay (ELISA). ELISA is a standard method for serological testing and is widely used for detecting and measuring antibodies against SARS-CoV-2. ELISA tests have a higher performance for detecting SARS-CoV-2 antibodies than lateral flow immunoassays but have lower sensitivity than chemiluminescence assays (Gong et al., 2021; Vengesai et al., 2021). Sensitivity and specificity of commercial ELISA tests for serological diagnosis of COVID-19 have been estimated to be greater than 83% and 97%, respectively (Vengesai et al., 2021). Anti-SARS-CoV-2 IgG positivity can be detected after an average of 12 days after exposure (Lynch et al., 2021). IgG titers decline over time but can still be detected among most patients after several months (He et al., 2021).

Plates were coated overnight at 4°C with 1 μ g/mL SARS-CoV-2 Spike-protein Receptor-Binding Domain (RBD) or SARS-CoV-2 Nucleocapsid Protein (NP) (GenScript, Piscataway, NJ) in 1X PBS. Plates were then blocked using blocking buffer (0.05% Tween-PBS 1X with 5% non-fat dry milk) for 1 h at room temperature followed by 3 washes with 0.05% Tween-PBS 1X (wash buffer). Heat-inactivated plasma samples were subjected to serial 3-fold dilutions in duplicate

with a starting dilution of 1:50. Plates were incubated for 1.5 h at room temperature. Plates were washed before detection with HRP-conjugated mouse anti-human IgG (dilution 1:4000, BD Biosciences, Franklin Lakes, NJ) and were incubated for 1.5 h at room temperature. Plates were washed and developed with o-phenylenediamine dihydrochloride (Sigma-Aldrich, St Louis, MI). The reaction was stopped by 1 M HCl. The optical density was measured at 490 nm using a Victor3 TM plate reader (PerkinElmer, Waltham, MA). End-point IgG titers were calculated using log-log transformation of the linear portion of the curve, and 0.1 OD units as cut-off. For each plate, a positive control sample was used to normalize ELISA titers among assays. IgG titer threshold was set at 2 standard deviations above the mean of plasma samples collected prior to SARS-CoV-2 pandemic.

Focus Reduction Neutralization Test (FRNT)

While ELISA tests are useful for measuring antibody titers in the sera, they do not provide information about the capacity of the antibodies to neutralize SARS-CoV-2. The FRNT is a neutralization assay that can estimate the functional capacity of anti-SARS-CoV-2 antibodies in the sera (Vanderheiden et al., 2020). FRNT is faster, has higher throughput, and is more accurate than other neutralization assays, such as plaque assays or cytopathic effect inhibition assays (Vanderheiden et al., 2020). Serially diluted heat inactivated plasma (1:3) were combined with 100 PFU of SARS-CoV-2 isolate USA-WA1/2020 (BEI resources) for 1 h before transferring to Vero E6 cells (ATCC C1008, ATCC, Manassas, VA) in 96-well plates. After 1 h, 1% methylcellulose (Sigma-Aldrich, St Louis, MI) at a 1:1 ratio was overlaid on the infected Vero cell layer and plates were incubated at 34°C for 24 h. After 24 h, the plates were fixed with 10% neutral buffered formalin (VWR, Radnor, PA) for 1 h before washing and addition of ice-cold methanol (Thermo Fisher Scientific, Hampton, NH) with 0.3% of hydrogen peroxide (Sigma-Aldrich, St. Louis, MO). Plates were incubated at -20° C for 10 min, then at room temperature for 20 min. Plates were then rinsed 3X with water and blocked for 1 h with 1X PBS plus 5% milk before adding anti-SARS nucleocapsid antibody (Novus Biologicals NB100-56576) at 1:1000 in 1X PBS plus 5% milk. Plates were developed by adding HRP anti-rabbit IgG antibody (Biolegend, San Diego, CA) and True Blue HRP substrate. Plates were imaged on an ELISpot reader (Autoimmun Diagnostika GmbH, Strassberg, Germany). Each plate contained a positive neutralization control and a negative control. FRNT 50 was calculated by non-linear regression analysis using normalized counted foci on Prism 7 (Graphpad Software, San Diego, CA).

Enzyme-Linked Immunosorbent Spot Assay (ELISpot)

EliSpot is a widely used method for measuring cellular immune response to antigens by detecting T cell activation. ELISpot allows for the measurement of individual cytokine-producing cells, which is not possible using ELISA (Schwarz et al., 2022). 300,000 PBMC/well were added to precoated anti-human IFN-y mAb ELISpot PLUS plates, MABTECH kit (Cincinnati, OH). Cells were then stimulated with 1 µg/well of SARS-CoV-2 peptides (15-mer with 9-mer overlap, Thermo Fisher Scientific) for 18 h at 37°C. Plates were then washed with PBS and biotinylated anti-human IFN- γ mAb (1 µg/mL) was added for 2 h at room temperature. After washing with PBS, plates were incubated for 1 h at room temperature with streptavidin-ALP. Following washing with PBS, BCIP-NBT-plus substrate was added, and the plates were developed until spots appeared. The number of SARS-CoV-2 specific IFN- γ secreting spot forming cells were counted in ELISpot reader (Autoimmun Diagnostika GmbH, Strassberg, Germany) using AID ELISpot 7.0 Software.

Statistical Analysis

Survey data were exported from RedCap into R v4.0.2 for analysis. Chi-squared tests and Fisher's Exact tests assessed changes in PPE availability and COVID-19 exposure over time. Two-sided *p*-values <0.05 were considered statistically significant. Spearman correlation analyses were performed with GraphPad Prism software.

Results

Study cohort characteristics

Overall, 289/299 study enrollees provided biological samples and were followed for up to 6 months. Most participants (84.1%; 243/289) made at least 2 sample collection visits, with 71.3% (206/289) providing samples at 3 or more visits (Figure 1). The majority of participants were female registered nurses (RN), aged 30-39. Participants were predominantly not of Hispanic or Latino ethnicity, and ~43% identified as white (Table 1). At baseline, 3.5% individuals reported household members suspected of COVID-19 and 0.7% with household members diagnosed with COVID-19. Overall, 52.2% participants reported providing care for COVID-19 patients at any time during the survey period. Across follow-up time points, up to 43.8% of individuals reported that they provided handson care for diagnosed COVID-19 patients and up to 19.7% performed or assisted with a medical operation with a high exposure risk to COVID-19 (Figure 2). Among the participants working in COVID-19 units, COVID-19 symptom level was low (6% or less) except for headaches but those were also high in participants not working in COVID-19 units (15.2% vs. 14.5%) (Table 1). Notably, during the entire study, none of the nasal swab samples collected during the scheduled visits were positive for SARS-CoV-2 by PCR virological testing (data not shown).




Figure 1. Study cohort characteristics.

PPE Availability and Occupational Exposure Risk to SARS-CoV-2

SARS-CoV-2 being a respiratory virus transmitted by aerosols and small droplets, the survey focused on PPE components that help prevent transmission of such viruses, including face masks (N95 respirators and surgical masks) as well as face shields and goggles that protect mucosa. Figure 3 shows the percentage of participants who reported availability of PPE "most of the time" or "always". Surgical masks were available for >88% of participants while N95 respirators were available for 84-88% of participants except in June/July when access decreased to 75%. Face shields and goggles became increasingly available with a gain of more than 20 points over the length of the survey. Similarly, protective clothing and round caps also became increasingly available, and around 50% of participants reported boot covers availability. In addition, gloves remained widely available over the entire study with more than 97% of participants stating that they had access to gloves most of the time or always (Figure 3).

SARS-CoV-2-Specific Humoral and Cellular Responses in HCPs

We first evaluated the longitudinal SARS-CoV-2 specific humoral response by measuring binding IgG antibody titers to nucleocapsid (NP) and spike receptor binding domain (RBD) by ELISA as well as by assessing virus neutralization (Table 2). At the first study visit (V1), NP-specific IgG antibodies were detected in 5 of the 289 participants for whom samples were obtained (1.7%) (Figure 4(A)), 3 of whom also had IgG specific to RBD (1.0% participants) (Figure 4(B)). Four additional HCP seroconverted between V1 and V2 while one HCP seroconverted between V2 and V3 (Figure 4(A) and (B)) thereby increasing the total number of HCP with a history of SARS-CoV-2 infection to 10 (3.5%). Participant 1 provided only a baseline sample (V1) that was positive for NP antibodies but negative for RBD (Figure 4(A) and (B)). The 3 participants with RBD-specific binding antibodies at the start of the study also had SARS-CoV-2 neutralizing antibodies (Figure 4(C)). Out of the 5 individuals who seroconverted during the study, four harbored antibodies against RBD and neutralizing antibodies against SARS-CoV-2 (Figure 4(B) and (C)). In addition, as previously reported (Wajnberg et al., 2020), significant correlations between RBD-specific and NPspecific IgG binding antibodies (Figure 4(D)) as well as between SARS-CoV-2 binding and neutralizing antibodies were observed (Figure 4(E)).

We then assessed if HCPs with detectable antibody responses also generated functional SARS-CoV-2 specific T cell responses (Table 2). PBMC from the 10 participants of interest were stimulated ex vivo with overlapping peptide pools covering the entire viral proteome and the number of SARS-CoV-2-specific T cells producing IFN-y was determined by INF-y ELISpot. All 10 participants with measurable antibody titers also developed SARS-CoV-2specific T cell responses which varied between subjects, visit timepoints and viral open reading frames (Figure 5). In addition, the kinetics of the response was subjectdependent with four participants (participants 3, 6, and 7) showing a decrease in T cell response over time while 2 participants (9 and 10) showed increasing response over time and one participant (8) showed an increase followed by a decrease in T cell response (Figure 5). In all 10 participants IFN-y T cell responses targeted structural proteins M, N and E, which are among the main targets of CD4 and CD8 T cell SARS-CoV-2 responses (Grifoni et al., 2021). S protein is also a main target and T cell responses in 8 participants targeted it while 5 and 8 did not at the timepoints tested. Non-structural proteins Nsp4-Nsp5 were targeted in all 10 participants. The 3 strongest responders (2, 3, and 6) targeted Nsp6-13, S part 2, ORF3a-E-M, Nsp14/ORF6-7a-7b-8-10 and N. Interestingly, while participants 6, 7, and 8 had binding antibody titers below the assay detection limit at Visit 1 (Figure 4(A)-(B)), they had measurable T cells responses at that timepoint. Furthermore, participant 6 had very strong responses against all tested peptide pools (Figure 5).

All 10 participants who seroconverted or entered the study with pre-existing antibody responses worked with COVID-19 patients and/or had COVID-19 patients in the unit(s) they worked in (Table 3). Six participants reported COVID-19 symptoms

	Assigned to Unit wit	h COVID Patients	
	No (N = 138)	Yes (N = 151)	Overall (N = 289)
Age, n (%)			
Ĩ8–29	23 (16.7%)	14 (9.3%)	37 (12.8%)
30–39	67 (48.6%)	63 (41.7%)	130 (45.0%)
40–49	34 (24.6%)	39 (25.8%)	73 (25.3%)
50+	14 (10.1%)	35 (23.2%)	49 (17.0%)
Gender, n (%)		(
Male	35 (25.4%)	14 (9.3%)	49 (17.0%)
Female	100 (72.5%)	134 (88.7%)	234 (81.0%)
Other/Non-binary	3 (2.2%)	3 (2.0%)	6 (2.1%)
Race/ethnicity, n (%)	× ,	()	()
White	62 (44.9%)	62 (41.1%)	124 (42.9%)
Asian	44 (31.9%)	39 (25.8%)	83 (28.7%)
Hispanic/Latino	17 (12.3%)	31 (20.5%)	48 (16.6%)
Pacific islander	3 (2.2%)	8 (5.3%)	(3.8%)
Black or African American	2 (1.4%)	I (0.7%)	3 (1.0%)
More than one race	5 (3.6%)	7 (4.6%)	12 (4.2%)
Other/Unknown	5 (3.6%)	3 (2.0%)	8 (2.8%)
Occupation, n (%)	5 (5.676)	3 (2.070)	0 (2.0%)
Advanced clinician ^a	6 (4.3%)	2 (1.3%)	8 (2.8%)
Clinical tech	13 (9.4%)	17 (11.3%)	30 (10.4%)
Clinical therapy ^b	17 (12.3%)	12 (7.9%)	29 (10.0%)
Other clinical	6 (4.3%)	15 (9.9%)	21 (7.3%)
Physician/Fellow/Resident	. ,	· ,	24 (8.3%)
Staff RN	18 (13.0%) 78 (E4 E%)	6 (4.0%)	· /
	78 (56.5%)	68 (45.0%)	146 (50.5%)
Administration	0 (0%)	11 (7.3%)	II (3.8%)
Clinical management	0 (0%)	20 (13.2%)	20 (6.9%)
Household member suspected of COVID, n (%) Yes	0 (0%)	10 (6 (9/)	
	0 (0%)	10 (6.6%)	10 (3.5%)
	138 (100%)	141 (93.4%)	279 (96.5%)
Household member diagnosed with COVID, n (%)	0 (00())	0 (1 00()	2 (0 70()
Yes	0 (0%)	2 (1.3%)	2 (0.7%)
No	138 (100%)	149 (98.7%)	287 (99.3%)
Slow breathing, n (%)			
Yes	0 (0%)	I (0.7%)	I (0.3%)
No	138 (100%)	150 (99.3%)	288 (99.7%)
Chest distress, n (%)	- // /- 0	- ///	- //
Yes	2 (1.4%)	3 (2.0%)	5 (1.7%)
No	136 (98.6%)	148 (98.0%)	284 (98.3%)
Headache, n (%)			
Yes	20 (14.5%)	23 (15.2%)	43 (14.9%)
No	118 (85.5%)	128 (84.8%)	246 (85.1%)
Diarrhea, n (%)			
Yes	6 (4.3%)	7 (4.6%)	13 (4.5%)
No	132 (95.7%)	144 (95.4%)	276 (95.5%)
Hemoptysis, n (%)			
Yes	0 (0%)	I (0.7%)	l (0.3%)
No	138 (100%)	150 (99.3%)	288 (99.7%)

Table 1. Demographic and Clinical Characteristics of Health Care Providers Assigned to and not Assigned to Units with COVID Patients.

note. ^aThe Advanced Clinician category included nurse practitioners, nurse anesthetists, and pharmacists. ^bThe Clinical Therapy category included activity therapist, occupational therapist, physical therapist, respiratory therapist, and speech pathologist.




Figure 2. Self-assessment surveys reporting longitudinal COVID-19 exposure risks. Participants (%) who worked in units with COVID-19 patients, participants (%) who performed or assisted with high-risk medical procedures. Sample size of participants in each time period include: April (n = 124), May (n = 242), June/July (n = 157), August/September (n = 194), October/November (n = 161).




Figure 3. Self-assessment surveys reporting longitudinal availability of PPE. Participants (%) reporting PPE "always" or "most of the time" for surgical masks; N95 respirators (survey of N95 respirators was added after the first visit so no data are available for April); face shields; goggles; gloves; protective clothing; round caps and boot covers. Sample size of participants in each time period include: April (n = 124), May (n = 242), June/July (n = 157), August/September (n = 194), October/November (n = 161).

during the study period and 2 reported being symptomatic prior to enrollment (Table 3). Of the 5 individuals who entered the study with pre-existing antibodies against SARS-CoV-2, 2 participants reported international travel (Table 3) and two reported social gathering without mask prior to study entry. In addition, of the 5 participants who seroconverted during the study, 2 individuals reported contact with family members with suspected/ confirmed COVID-19 diagnosis (Table 3). Therefore, it is possible that some infections occurred in the community and not in the hospital where strict masking policies and infection control measures were in place.

Discussion

It is widely believed that, due to their occupation, health care workers are at a significantly increased risk of SARS-CoV-2 exposure and infection. However, this risk is difficult to assess given that most infections are asymptomatic. In this study, we

Assay	lmmunological Marker	Physiological Significance
ELISA	lgG	IgG binding antibody specific for SARS-CoV-2 receptor binding domain (RBD) of spike protein or for SARS-CoV-2 nucleocapsid (N) protein
FRNT	Neutralizing antibody	Detection of functional antibodies able to neutralize SARS-CoV-2 virus and prevent cell entry
ELISpot	tIFNγ	Detection of IFN γ cytokine produced by T cells that recognize specific SARS-CoV-2 peptides

Table 2. Characterization of Biological Markers and Measurement Targets.




Figure 4. Humoral responses in healthcare workers who seroconverted. (A and B) Longitudinal IgG endpoint antibody titers directed against NP (A) or RBD (B) from HCP who seroconverted. (C) Longitudinal neutralizing antibody titers from HCP who developed binding antibody responses. Dashed lines in panels (A–C) are the limit of detection thresholds that were defined using pre-pandemic plasma samples. (D) Correlation between NP-specific and RBD-specific IgG antibody end-point binding antibody titers. (E) Correlation between antibody neutralization titers and IgG specific end-point binding antibody titers. P and r values in grey for RBD and in black for NP datasets.

assessed the rate of asymptomatic, subclinical SARS-CoV-2 infection of HCPs during the summer 2020 surge at a large American urban medical center by integrating serological responses and self-reported risk exposure surveys to better understand the association between risk exposure and infection.

Overall, the participants' exposure risk at UCI Medical Center was high as 48–69% participants worked in COVID-19 units and more than 30% participants cared for COVID-19 patients. Nevertheless, infection rate was low with only 2.1% seroconversion rate (5/243) during the study timeframe, likely due to good adherence to infection prevention measures and high PPE use as surgical masks were widely available throughout the study and N95 respirator availability increased over time. This low seroconversion rate is consistent with a study that was also conducted in Orange County during May-June 2020 which observed similar findings of a low seroprevalence of 1.13% (Brant-Zawadzki et al., 2020). Another study performed in April-May 2020 at an integrated healthcare system in Indiana also observed a low SARS-CoV-2 prevalence of 1.6%. Notably there was no statistically significant difference in seroconversion level between employees from high-risk settings and those in low-risk settings (Brant-Zawadzki et al., 2020; Hunter et al., 2020). In addition, both studies were conducted around May 2020 when their respective institutions also had guidelines already in place for PPE use and other infection prevention measures. In contrast, in a study conducted in London, England in March 2020, 25% of participants were seropositive at study entry and 20% of HCPs seroconverted during the study; notably, strict PPE guidelines were not introduced until April 1, 2020 in England (Houlihan et al., 2020).

Despite the occupational risk of exposure for HCP, because only 5 out of 243 participants seroconverted during this longitudinal study, we propose that the occupational risk does not appear to be higher than the community risk in surrounding Orange County at the time. Indeed, the infection level for HCP in other studies was no different from the concurrent infection rate in the general population (Brant-Zawadzki et al., 2020; Hunter et al.,




Figure 5. T cell responses in healthcare workers who seroconverted. Heatmap representing the frequency of antigen-specific T cell IFN- γ production determined by ELISPOT assay. Color scale is based on the lowest and highest value of the data included. Each row represents a participant's visit and each column a specific pool of overlapping peptides.

2020). This would also explain that while we collected extensive survey data on seroconverted HCPs in terms of their occupational exposure risks during the study time frame, no reliable patterns emerged (see Table 3). Binding and neutralizing antibody levels in seroconverted HCP

remained fairly stable during the length of the study. Interestingly, participants 1 and 5 were positive for N-specific binding antibodies but negative for RBDspecific antibodies. RBD is located in the S1 subunit of the spike protein and investigations of kinetics of SARS-

			Occupational Exposure Risk	posure Risk			Community Exposure Risk	oosure Risk		
Participant	Time of t Seroconversion	Symptoms And/Or COVID-19 Diagnostic Patients in 1	COVID-19 Patients in Unit	Contact with COVID-19 Persons in Unit	Care of COVID-19 Patients	High Exposure Risk Household Procedure on COVID-19 COVID-19 Patients Contact	Household COVID-19 Contact	Exposure to People Suspected/ Diagnosed	Travel	Social Gathering
_	Prior to VI	Symptomatic prior Prior to VI to VI	Prior to VI	Prior to VI					Prior to VI	Prior to VI
7	Prior to VI	Symptomatic prior Prior to VI to VI	Prior to VI	Prior to VI	Prior to VI	Prior to VI			:	Prior to VI
e	Prior to VI	Ŋ. Ŋ.	Prior to VI	Prior to VI	Prior to VI	Prior to VI			Prior	
4	Prior to VI	Symptomatic prior to VI							5	
S	Prior to VI	2 Ž	Suspected COVID-19 patient(s) prior to VI							
9	VI-V2	VI-V2	VI-V2				Prior to VI & VI-V2	Prior to VI		
٢	VI-V2	Symptomatic VI- V2, positive test VI-V2	Prior to VI & VI-V2	Prior to VI & VI-V2	Prior to V2		l - -			
8	VI-V2	Tested positive VI- Prior to VI & V2 V1-V2	Prior to VI & VI-V2	Prior to VI & VI-V2	Prior to VI & VI-V2	Prior to VI & VI-V2				
6	VI-V2	Symptomatic VI- V2	Prior to VI & VI-V2	Prior to VI & VI-V2	Prior to VI & VI-V2	Prior to VI & VI-V2				
0	V2-V3	Symptomatic V2- V3		Prior to VI & VI-V2	Suspected COVID-19 patient(s) prior to VI			V2-V3		

Table 3. Occupational & Community Exposure History among Health Care Providers with SARS-CoV-2 Seroconversion.

CoV-2 antibodies revealed discrepancies with some studies showing that spike-specific antibody levels were higher than S1-specific antibodies (Fenwick et al., 2021) while others revealed earlier detection and higher RBD-specific antibody levels compared to S1-specific antibodies (Brochot et al., 2020), thus measuring anti-spike antibodies in our cohort could have yielded different results. In addition, in asymptomatic subjects, N-specific antibody levels were higher than S1- and S2-specific antibody levels and in symptomatic patients N-specific antibody titers reached higher levels earlier after symptom onset than RBD-specific and spike-specific titers (Brochot et al., 2020; Burbelo et al., 2020). The kinetics of functional T cell responses was more dynamic than the antibody responses and T cell response levels were also participant- and timepointdependent as observed by Kim et al. who noted peak T cell responses specific for S1, S2 and N antigens 1 month post symptom onset (Kim et al., 2021).

Limitations and Conclusion

Although data were collected rigorously, study limitations include collection from a single urban academic medical center and a small sample size that arguably did not represent the HCP population at large. Potential biases include voluntary participation of study population that conceivably was already aware of risk and therefore enrolled because of the regular testing provided. We also recognize a potential bias towards nurses, who constituted 50% of the sample, and the non-representation of HCPs involved with risky procedures, such as interventional pulmonologists. Despite these limitations, our study findings indicate that working as a HCP at a large urban academic medical center does not necessarily equate to higher risk when PPE is widely available.

Acknowledgments

We thank all HCPs who participated in this study. We would like to thank Dr. Izabela Coimbra Ibraim and Mr. Allen Jankeel for technical assistance.

Author Contributions

SS: Conceptualization, obtained funding, managed data and specimen collection.

- MB: Conceptualization, obtained funding, participant recruitment. DCM: Figure preparation, wrote first draft.
- HV: Data analysis, co-wrote first draft.

BMD: Laboratory experiments, data analysis.

IM: Conceptualization, obtained funding, managed laboratory experiments.

All authors contributed to editing the manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by COVID-19 Basic, Translational and Clinical Research Fund from UC Irvine Office of the Vice Chancellor for Research and UL1TR001414–06 (NIH/NCATS).

References

- Bielicki, J. A., Duval, X., Gobat, N., Goossens, H., Koopmans, M., Tacconelli, E., & van der Werf, S. (2020). Monitoring approaches for health-care workers during the COVID-19 pandemic. *The Lancet Infectious Diseases*, 20(10), e261–e267. https://doi.org/10.1016/S1473-3099(20)30458-8
- Brant-Zawadzki, M., Fridman, D., Robinson, P. A., Zahn, M., Chau, C., German, R., Breit, M., Bock, J. R., & Hara, J. (2020). SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single center study. *PLoS One*, *15*(11), e0240006. https://doi.org/10.1371/journal.pone.0240006
- Brochot, E., Demey, B., Touze, A., Belouzard, S., Dubuisson, J., Schmit, J. L., Duverlie, G., Francois, C., Castelain, S., & Helle, F. (2020). Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals. *Frontiers in Microbiology*, *11*(**•••**), 584251. https://doi. org/10.3389/fmicb.2020.584251
- Burbelo, P. D., Riedo, F. X., Morishima, C., Rawlings, S., Smith, D., Das, S., Strich, J. R., Chertow, D. S., Davey, R. T., & Cohen, J. I. (2020). Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. *The Journal* of Infectious Diseases, 222(2), 206–213. https://doi.org/10. 1093/infdis/jiaa273
- Daria, S., & Islam, M. R. (2022). The SARS-CoV-2 omicron wave is indicating the end of the pandemic phase but the COVID-19 will continue. *Journal of Medical Virology*, 94(6), 2343–2345. https://doi.org/10.1002/jmv.27635
- Eyre, D. W., Lumley, S. F., O'Donnell, D., Campbell, M., Sims, E., Lawson, E., Warren, F., James, T., Cox, S., Howarth, A., Doherty, G., Hatch, S. B., Kavanagh, J., Chau, K. K., Fowler, P. W., Swann, J., Volk, D., Yang-Turner, F., Stoesser, N., & Walker, T. M. (2020). Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. *Elife*, *9*, e60675. https://doi.org/10.7554/eLife.60675
- Fenwick, C., Croxatto, A., Coste, A. T., Pojer, F., Andre, C., Pellaton, C., Farina, A., Campos, J., Hacker, D., Lau, K., Bosch, B. J., Gonseth Nussle, S., Bochud, M., D'Acremont, V., Trono, D., Greub, G., & Pantaleo, G. (2021). Changes in SARS-CoV-2 spike versus nucleoprotein antibody responses impact the estimates of infections in population-based seroprevalence studies. *Journal of Virology*, *95*(3), e01828-20. https://doi.org/10. 1128/JVI.01828-20
- Gong, F., Wei, H. X., Li, Q., Liu, L., & Li, B. (2021). Evaluation and comparison of serological methods for COVID-19 diagnosis.

Frontiers in Molecular Biosciences, 8(**•••**), 682405. https://doi.org/10.3389/fmolb.2021.682405

- Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D., & Sette, A. (2021). SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. *Cell Host & Microbe*, 29(7), 1076–1092. https://doi.org/10.1016/j.chom.2021.05.010
- He, Z., Ren, L., Yang, J., Guo, L., Feng, L., Ma, C., Wang, X., Leng, Z., Tong, X., Zhou, W., Wang, G., Zhang, T., Guo, Y., Wu, C., Wang, Q., Liu, M., Wang, C., Jia, M., Hu, X., & Wang, C. (2021). Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: A longitudinal, population-level, cross-sectional study. *Lancet*, 397(10279), 1075–1084. https://doi.org/10.1016/S0140-6736(21)00238-5
- Houlihan, C. F., Vora, N., Byrne, T., Lewer, D., Kelly, G., Heaney, J., Gandhi, S., Spyer, M. J., Beale, R., Cherepanov, P., Moore, D., Gilson, R., Gamblin, S., Kassiotis, G., McCoy, L. E., Swanton, C., Crick COVID-19 ConsortiumHayward, A., & Nastouli, E.SAFER Investigators. (2020). Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline healthcare workers. *Lancet*, 396(10246), e6–e7. https://doi.org/10. 1016/S0140-6736(20)31484-7
- Hughes, M. M., Groenewold, M. R., Lessem, S. E., Xu, K., Ussery,
 E. N., Wiegand, R. E., Qin, X., Do, T., Thomas, D., Tsai, S.,
 Davidson, A., Latash, J., Eckel, S., Collins, J., Ojo, M.,
 McHugh, L., Li, W., Chen, J., Chan, J., & Stuckey, M. J. (2020).
 Update: Characteristics of health care personnel with COVID-19–United States, February 12–July 16, 2020. *MMWR. Morbidity and Mortality Weekly Report*, 69(38), 1364–1368. https:// doi.org/10.15585/mmwr.mm6938a3
- Hunter, B. R., Dbeibo, L., Weaver, C. S., Beeler, C., Saysana, M., Zimmerman, M. K., & Weaver, L. (2020). Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure. *Infection Control and Hospital Epidemiology*, *41*(12), 1441–1442. https://doi.org/10.1017/ice.2020.390
- Ip, M., Chan, P. K. S., Lee, N., Wu, A., Ng, T. K. C., Chan, L., Ng, A., Kwan, H. M., Tsang, L., Chu, I., Cheung, J. L. K., Sung, J. J. Y., & Tam, J. S. (2004). Seroprevalence of antibody to severe acute respiratory syndrome (SARS)-associated coronavirus among health care workers in SARS and non-SARS medical wards. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 38(12), e116–e118. https://doi.org/10.1086/421019
- Kim, J. Y., Kwon, J. S., Bae, S., Cha, H. H., Lim, J. S., Kim, M. C., Chung, J. W., Park, S. Y., Lee, M. J., Kim, B. N., Jung, J., Kim, M. J., Shin, E. C., & Kim, S. H. (2021). SARS-CoV-2-Specific antibody and T cell response kinetics according to symptom severity. *The American Journal of Tropical Medicine and Hygiene*, 105(2), 395–400. https://doi.org/10.4269/ajtmh.20-1594
- Kucharski, A. J., & Nilles, E. J. (2020). Using serological data to understand unobserved SARS-CoV-2 risk in health-care settings. *The Lancet. Infectious Diseases*, 20(12), 1351–1352. https://doi.org/10.1016/S1473-3099(20)30579-X

- Lynch, K. L., Whitman, J. D., Lacanienta, N. P., Beckerdite, E. W., Kastner, S. A., Shy, B. R., Goldgof, G. M., Levine, A. G., Bapat, S. P., Stramer, S. L., Esensten, J. H., Hightower, A. W., Bern, C., & Wu, A. H. B. (2021). Magnitude and kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 72(2), 301–308. https://doi.org/10.1093/cid/ciaa979
- McCauley, L., & Hayes, R. (2020). Taking responsibility for frontline health-care workers. *The Lancet. Public Health*, 5(9), e461-e462. https://doi.org/10.1016/S2468-2667(20)30179-1
- National Nurses United. (2020). New survey of nurses provides frontline proof of widespread employer, government disregard for nurse and patient safety, mainly through lack of optimal PPE.
- Nguyen, L. H., Drew, D. A., Graham, M. S., Joshi, A. D., Guo, C. G., Ma, W., Mehta, R. S., Warner, E. T., Sikavi, D. R., Lo, C. H., Kwon, S., Song, M., Mucci, L. A., Stampfer, M. J., Willett, W. C., Eliassen, A. H., Hart, J. E., Chavarro, J. E., & Rich-Edwards, J. W.Coronavirus Pandemic Epidemiology Consortium. (2020). Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study. *The Lancet Public Health*, 5(9), e475–e483. https://doi.org/10. 1016/S2468-2667(20)30164-X
- Richterman, A., Meyerowitz, E. A., & Cevik, M. (2020). Hospitalacquired SARS-CoV-2 infection: Lessons for public health. *JAMA*, 324(21), 2155–2156. https://doi.org/10.1001/jama.2020.21399
- Schwarz, M., Mzoughi, S., Lozano-Ojalvo, D., Tan, A. T., Bertoletti, A., & Guccione, E. (2022). T cell immunity is key to the pandemic endgame: How to measure and monitor it. *Current Research in Immunology*, *3*, 215–221. https://doi.org/10.1016/j. crimmu.2022.08.004
- Tran, K., Cimon, K., Severn, M., Pessoa-Silva, C. L., & Conly, J. (2012). Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review. *PLoS One*, 7(4), e35797. https://doi.org/10. 1371/journal.pone.0035797
- Vanderheiden, A., Edara, V. V., Floyd, K., Kauffman, R. C., Mantus, G., Anderson, E., Rouphael, N., Edupuganti, S., Shi, P. Y., Menachery, V. D., Wrammert, J., & Suthar, M. S. (2020). Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies. *Current Protocols in Immunology*, 131(1), e116. https://doi.org/10.1002/cpim.116
- Vengesai, A., Midzi, H., Kasambala, M., Mutandadzi, H., Mduluza-Jokonya, T. L., Rusakaniko, S., Mutapi, F., Naicker, T., & Mduluza, T. (2021). A systematic and meta-analysis review on the diagnostic accuracy of antibodies in the serological diagnosis of COVID-19. *Systematic Reviews*, 10(1), 155. https://doi. org/10.1186/s13643-021-01689-3
- Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., Stadlbauer, D., Stone, K., Strohmeier, S., Simon, V., Aberg, J., Reich, D. L., Krammer, F., & Cordon-Cardo, C. (2020). Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*, *370*(6521), 1227–1230. https:// doi.org/10.1126/science.abd7728